Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Fig. 2

Number of immune checkpoint inhibitor FDA approvals by year: The colors in the key denote the predictiveness and approval status of PD-L1 status as a companion diagnostic. The labeled tumor types (in blue) represent approvals with PD-L1 testing as a companion diagnostic. Abbreviations: GEJ = gastroesophageal junction, NSCLC = non-small cell lung cancer

Back to article page